Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 17Leukemia 12Breast Neoplasms 12Prostatic Neoplasms 10Neoplasm Metastasis 8Recurrence 6Pancreatic Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Non-Small-Cell Lung 6Melanoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Philadelphia Chromosome 4Multiple Myeloma 4Lymphoma 4Burkitt Lymphoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Ovarian Neoplasms 3Glioma 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Neuroblastoma 2Leukemia, Myelomonocytic, Chronic 2

Interventions

vandetanib 1ruxolitinib 1pazopanib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Ifosfamide 1Everolimus 1Etoposide 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Carboplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Relapsed Pediatric Solid Tumor × Dasatinib × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡